Microfluidic engineering for organoid formation, cultivation, and sensing
In brief
Microfluidic systems target organoid culture limits, but standardization remains unresolved
This review maps how microfluidic platforms can support organoid formation, long-term culture and real-time sensing by controlling flow, stimulation, cell interactions and monitoring. These approaches address limits of static culture, including poor transport and missing vasculature, but reproducibility, standardization and sensor integration remain barriers. Their value for personalized medicine and reducing animal use still needs to be established.
- Journal
- Frontiers in bioengineering and biotechnology (Q1)
- Published
- 4 November 2026
- Study design
- Narrative review / expert opinion
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- I A Kushnir, K O Salina, Y A Bogolubova, T M Mushegian, M A Dragun, D D Volegova, et al.
- PMID
- 43054676
- DOI
- 10.3389/fbioe.2026.1994650
Why clinicians should know about it
- Picked for Embryology (paper of the day, 22 November 2026): Review of organoid models for morphogenesis and organogenesis
Abstract
Organoids have emerged as powerful in vitro models for studying tissue morphogenesis, organogenesis, and disease mechanisms. However, they are typically generated and maintained in static culture without perfusion, a configuration that imposes fundamental biophysical constraints and thereby restricts their physiological relevance. This review examines how microfluidic engineering addresses these limitations across the entire organoid workflow, from formation and long-term culture to integrated biosensing. First, we analyze how material selection, flow actuation, and channel hydrodynamics define the engineering basis for controlled microenvironments. We then classify microfluidic architectures by function: geometric confinement and droplet microfluidics for organoid formation; mechanical stimulation, vascularization, co-cultivation, and gradient control for long-term culture; and on-chip imaging with physical and biochemical sensors for real-time monitoring. By mapping these engineering solutions onto specific biological bottlenecks-diffusion-limited transport, the absence of vasculature, and sparse inter-tissue crosstalk-we identify persistent challenges in reproducibility, standardization, and sensor integration. Finally, we discuss the path toward regulatory qualification of such platforms and their potential to advance personalized medicine while reducing reliance on animal testing.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.